# SARS-CoV-2 Spike glycoprotein [ChAdOx1-S]

## COVID-19 Vaccine AstraZeneca 0.5mL/dose (5mL/vial)

##### 

| Title              | Content                                                                                                                                                                                                         |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TAH Drug Code      | ICOVAZ                                                                                                                                                                                                          |
| Indications        | AstraZeneca COVID-19 Vaccine is indicated for active immunization of individuals 18 years of age and older for the prevention of coronavirus disease 2019 (COVID-19).                                           |
| Dosing             | IM， 0.5 mL， > or = 18 years 2 doses administered 4 to 12 weeks apart. (Taiwan CDC suggests 2 doses administered 8 to 12 weeks apart.)                                                                         |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                   |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                   |
| Contraindications  | History of a severe allergic reaction after a previous dose or to a component of the formulation; history of immediate allergic reaction to a previous dose; known allergy to any component of the formulation. |
| Adverse Effects    | erythema at injection site， pain at injection site， and swelling at injection site. asthenia， fatigue， fever， headache， myalgia， and nausea.                                                             |
| Pregnancy          | Unknown                                                                                                                                                                                                         |
| Lactation          | Unknown                                                                                                                                                                                                         |

